Loading...
Please wait, while we are loading the content...
Similar Documents
The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients
| Content Provider | PubMed Central |
|---|---|
| Author | Al-marrawi, Mhd Y. Rini, Brian I. Harshman, Lauren C. Bjarnason, Georg Wood, Lori Vaishampayan, Ulka Mackenzie, Mary Knox, Jennifer J. Agarwal, Neeraj Al Harbi, Hulayel Kollmannsberger, Christian Tan, Min-han Rha, Sun Young Donskov, Frede N. North, Scott Choueiri, Toni K. Heng, Daniel Y. |
| Copyright Year | 2013 |
| Abstract | There are many active drugs to treat metastatic renal cell carcinoma (mRCC) patients who progress through their first-line vascular endothelial growth factor (VEGF) inhibitor. Many clinicians choose a second-line VEGF inhibitor based on the type of response to first-line VEGF inhibitor, without data supporting this practice. This study was conducted to determine the association of response to second-line VEGF inhibitor with response to first-line VEGF inhibitor. All mRCC patients in participating centers of the International mRCC Database Consortium who were treated from January 2004 through June 2011 with a second-line VEGF inhibitor after failure of a different first-line VEGF inhibitor were retrospectively identified. The primary outcome is objective response rate (ORR) and the secondary outcome is progression-free survival (PFS) in each line of therapy. Of 1,602 total database patients, 464 patients received a first- and second-line VEGF inhibitor. The ORR to first-line therapy was 22 %, and the ORR to second-line therapy was 11 %. The ORR to second-line therapy was not different among patients achieving partial response versus stable disease versus progressive disease to first-line therapy (14 % vs. 10 % vs. 11 %, respectively; chi-squared trend test p=0.17). The median PFS on first-line VEGF-targeted therapy was 7.5 months (95 % CI, 6.6–8.1), and the median PFS on second-line VEGF inhibitor was 3.9 months (95 % CI, 3.6–4.5). There was no correlation between first-line and second-line PFS (Pearson correlation coefficient 0.025; p=0.59). The clinical response to a second-line VEGF inhibitor is not dependent on response to the first-line VEGF-inhibitor. Further studies are needed to define clinical parameters that predict response to second-line therapy to optimize the sequence of VEGF-targeted therapy in metastatic RCC patients. |
| Related Links | http://dx.doi.org/10.1007/s11523-012-0252-7 |
| Ending Page | 209 |
| Page Count | 7 |
| Starting Page | 203 |
| File Format | |
| ISSN | 17762596 |
| e-ISSN | 1776260X |
| Journal | Targeted oncology |
| Issue Number | 3 |
| Volume Number | 8 |
| Language | English |
| Publisher Date | 2013-09-01 |
| Access Restriction | Open |
| Subject Keyword | Pharmacology (medical) Cancer Research Oncology Research in Higher Education |
| Content Type | Text |
| Resource Type | Article |
| Subject | Cancer Research Pharmacology (medical) Oncology |
